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Abstract
Background: Excitotoxic neuronal injury by action of the glutamate receptors of the N-methyl-
d-aspartate (NMDA) subtype have been implicated in the pathogenesis of brain damage as a
consequence of bacterial meningitis. The most potent and selective blocker of NMDA receptors
containing the NR2B subunit is (R,S)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-
piperid inepropanol (RO 25-6981). Here we evaluated the effect of RO 25-6981 on hippocampal
neuronal apoptosis in an infant rat model of meningitis due to Streptococcus pneumoniae. Animals
were randomized for treatment with RO 25-6981 at a dosage of either 0.375 mg (15 mg/kg; n =
28) or 3.75 mg (150 mg/kg; n = 15) every 3 h or an equal volume of sterile saline (250 µl; n = 40)
starting at 12 h after infection. Eighteen hours after infection, animals were assessed clinically and
seizures were observed for a period of 2 h. At 24 h after infection animals were sacrificed and
brains were examined for apoptotic injury to the dentate granule cell layer of the hippocampus.
Results: Treatment with RO 25-6981 had no effect on clinical scores, but the incidence of seizures
was reduced (P < 0.05 for all RO 25-6981 treated animals combined). The extent of apoptosis was
not affected by low or high doses of RO 25-6981. Number of apoptotic cells (median [range]) was
12.76 [3.16–25.3] in animals treated with low dose RO 25-6981 (control animals 13.8 [2.60–31.8];
(P = NS) and 9.8 [1.7–27.3] (controls: 10.5 [2.4–21.75]) in animals treated with high dose RO 25-
6981 (P = NS).
Conclusions: Treatment with a highly selective blocker of NMDA receptors containing the NR2B
subunit failed to protect hippocampal neurons from injury in this model of pneumococcal
meningitis, while it had some beneficial effect on the incidence of seizures.
Background
Bacterial meningitis is the most common serious infection
of the central nervous system and, despite the use of
highly effective antibiotics, is fatal in 5–25% of patients
and causes neurologic sequelae in up to 30% of the survi-
vors [1]. Two forms of neuronal injury have been identi-
fied. The first form consists of necrotic injury in the cortex
and is reduced by therapies that prevent the development
of ischemia [2]. The second form consists of apoptosis in
the dentate gyrus of the hippocampus. It may be respon-
sible for learning and memory deficits observed after
meningitis [2].
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Neuronal damage during meningitis may be caused by
excitatory amino acids (EAA) [3]. The NMDA subtype of
EAA receptors is believed to be responsible for excitotoxic
cell death associated with neuronal disorders and injury
[4,5]. NMDA receptors are composed of an association of
subunits that belong to two families: a single gene product
(NR1) with eight splice variants and four different NR2
subunits (NR2A, B, C, D) produced by a different gene [6].
Within the brain, the NR1, NR2A and NR2B subunits are
more prominent in cortical areas and the hippocampus
than in white matter and cerebellum [7]. The NR2B subu-
nits are expressed at highest levels in the hippocampus,
cerebral cortex and olfactory bulb [8]. During early post-
natal development, NR2B subunits may have a more
dominant role than NR2A in modulating NMDA recep-
tors throughout the CNS [9]. Recently, NR2B-selective
NMDA antagonists have been developed that are protec-
tive in focal cerebral ischemia [8,10]. RO 25-6981 is a
noncompetitive, highly selective, activity-dependent
blocker of NMDA receptors that contain the NR2B subu-
nit [11]. The aim of the present study was to evaluate the
effect of the NR2B-selective NMDA antagonist RO 25-
6981 on hippocampal injury and seizures in an infant rat
model of meningitis due to Streptococcus pneumoniae.
Methods
Infant rat model of bacterial meningitis
The animal studies were approved by the Animal Care and
Experimentation Committee of the Canton of Bern, Swit-
zerland and followed National Institutes of Health guide-
lines for the performance of animal experiments.
Nursing Sprague-Dawley rat pups with their dam were
purchased (RCC Biotechnology & Animal Breeding, Fül-
linsdorf, Switzerland) and pups were infected on postna-
tal day 11. A clinical strain of Streptococcus pneumoniae
(type 3) was used. Ten µl of a suspension of the organism
in normal saline produced from a log-phase culture was
directly injected into the cisterna magna [2,12]. The inoc-
ulum size was ~log10 6.3 colony forming units/ml. Eight-
een hours after infection, all animals were weighed and
assessed clinically. Clinical severity of disease was scored
in each animal and was graded as follows: 1 = coma; 2 =
does not turn upright; 3 = turns upright within 30 s; 4 =
minimal ambulatory activity; 5 = normal. Seizures as
defined by tonic convulsions for >15 sec were observed
for a period of two hours (i.e. from 18 to 20 h after
infection).
To document meningitis, 10–30 µl of CSF was obtained at
18 h after infection by puncture of the cisterna magna and
was cultured quantitatively on blood-agar plates and incu-
bated for 24 h at 37°C with 5 % CO2. All animals were
subsequently treated with antibiotics (ceftriaxone, 100
mg/kg subcutaneously once; Roche Pharma, Basel, Swit-
zerland) as untreated animals die from the disease within
20–22 h after infection.
Animals were sacrificed with an overdose of pentobarbital
(100 mg/kg intraperitoneally) at 24 h after infection or
when they became terminally ill (cyanotic, severe dysp-
nea, protracted seizures).
Treatment regimens
Animals were randomized for treatment with RO 25-6981
(kindly provided by Dr. G. Fischer, Roche Pharma, Basel,
Switzerland) or an equal volume of sterile saline (250 µl;
n = 40) starting at 12 h after infection. Animals treated
with RO 25-6981 received either 0.375 mg (15 mg/kg =
low dose; n = 28) or 3.75 mg = (150 mg/kg = high dose; n
= 15) subcutaneously every 3 h.
Histomorphometry
Immediately after sacrifice, animals were perfused via the
left cardiac ventricle with 15 ml of 4% paraformaldehyde
in phosphate buffered saline (pH 7.4). Brains were cut at
45-µm intervals on a cryostat (Cryocut 1800; Leica Instru-
ments, Nussloch, Germany) to obtain 12 coronal section.
Only animals that survived > 18 h were included for the
analysis of neuronal damage, since previous studies had
shown that apoptosis is not reliably detected prior to 18 h
after infection. Sections were stained with cresyl violet.
For quantitative evaluation, coronal sections were exam-
ined for injury to the dentate granule cell layer of the hip-
pocampus. Cells with morphologic changes compatible
with apoptosis (condensed or fragmented nuclei, Figure
1) were counted in 3 visual fields (×400) in each of the
four blades of the dentate gyrus. An averaged score per
animal was calculated from all sections evaluated. All his-
topathologic evaluations were performed by an investiga-
tor blinded to the clinical, microbiological and treatment
data of animals.
Statistics
Bacterial titers in the CSF were compared with the
unpaired t-test. Incidence of seizures and spontaneous
death were compared using Fisher's exact test. The score of
hippocampal apoptosis was analyzed with the Mann-
Whitney test. The clinical activity score and weight at 18 h
were compared with one way ANOVA and the Newman-
Keuls post-hoc test for multiple comparison. Probabilities
≤ 0.05 were considered significant.
Results
Clinical outcome
Eighteen hours after infection, all infected animals had
fully developed meningitis, as evidenced by lethargy or
obtundation and by positive bacterial CSF titers. Treat-
ment of animals with RO 25-6981, beginning at 12 h after
infection, had no influence on bacterial titers in CSF orBMC Neuroscience 2003, 4 http://www.biomedcentral.com/1471-2202/4/21
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clinical score (Table 1). Spontaneous death occurred more
frequently (p < 0.02) in animals which received the higher
dose of RO 25-6981 compared to animals treated with the
lower dose. Mortality was not significantly different for all
treated animals combined vs. saline controls and for the
two treatment groups alone vs. their respective controls
(Table 1). Between 18 and 20 h after infection, seizures
occurred in 3/28 of animals treated with the low dose of
RO 25-6981, compared to 7/28 of the corresponding
saline controls. Similarly, animals treated with ten times
higher dose of RO 25-6981 had a frequency of seizures of
1/15 compared to 4/12 in the corresponding controls. The
differences in the incidence of seizures did not reach sta-
tistical significance when treatment groups were com-
pared with their respective controls alone. However,
comparison of seizure frequency of all treated animals (4/
43) with that of the saline controls (11/40) revealed a sig-
nificant (P < 0.05) reduction in animals treated with RO
25-6981.
Hippocampal injury
In all groups, there was apoptosis in the dentate gyrus
(Figure 1). In the group of animals treated with the low
doses of RO 25-6981, the median and [range] number of
apoptotic cells was 12.76 [3.16–25.3], compared to 13.8
[2.60–31.8] in saline treated control animals (P = NS).
Similarly, treatment with the higher doses of RO 25-6981
did not significantly reduce the number of apoptotic cells
in comparison to saline treated controls (9.8 [1.7–27.3] vs
10.5 [2.4–21.75]; P = NS).
Discussion
Several observations led to the exploration of the role of
EAA in causing seizures and apoptotic neuronal injury in
the hippocampus. First, glutamate concentrations are
markedly increased in the brain extracellular fluid and in
the CSF during bacterial meningitis [3,13]. Of note, the
dentate gyrus of the hippocampus is in close vicinity of
ventricular space. It is therefore conceivable that gluta-
mate may diffuse into this brain structure from the CSF in
the ventricular space, when concentrations of the EAA are
increased during meningitis [14]. This is important in the
current context, since direct ischemia, with subsequent
local release of glutamate within the hippocampal tissue
does not appear to be the primary mechanism of injury to
this structure during meningitis [2]. Secondly, at certain
concentrations, glutamate tends to induce apoptosis
rather than necrosis in the brain [15–17]. This is of inter-
est in the context of the hypothesis that glutamate may
diffuse into the parenchyma of the hippocampus from the
CSF in the ventricular system. This could lead to relatively
moderate increases of extracellular glutamate concentra-
tions, particularly if the local astrocytes maintain some
glutamate scavenging functions, thus favoring apoptosis
over necrosis. Finally, our earlier results in a model of
group B streptococcal meningitis have indicated that the
non-specific inhibitor of glutamate receptors, kynurenic
acid, was protective in the hippocampus [18].
The failure of the drug to protect from structural damage
despite its functional benefits (seizures) does not appear
to result from insufficient dosing. We have used doses
found previously to be effective in rats [19], and a 10-fold
increased dose, which was high enough to show signs of
toxicity (increased mortality) was not more effective than
the standard dose. Furthermore, RO 25-6981 suppressed
seizures, indicating that the drug did indeed penetrate
into the brain in therapeutically relevant concentrations.
Antagonists of NMDA receptors are powerful anticonvul-
sants in many animal models of epilepsy [20]. One obvi-
ous reason for the lack of neuroprotection may be that
NMDA receptor stimulation by EAA is not causing apop-
totic injury to the dentate gyrus. Our study with kynurenic
acid, while showing some protection in the dentate gyrus,
did not specifically examine whether it was the apoptotic
form of injury that was prevented [18]. Another explana-
tion may lie in the fact that beginning at about postnatal
day 12, the levels of NR2B protein decline rapidly and
reach undetectable levels by 22 days after birth [9]. The
animals in our study were 12 days old at the time of ther-
apy, an age where the NR2B subunit can still be docu-
mented immunocytochemically [21]. Nevertheless, it is
Table 1: Effect of RO 25-6981 on clinical parameters in experimental bacterial meningitis
Low dosage study High dosage study
0.9% NaCl (250 µl) RO 25-6981 (15 mg/kg) 0.9% NaCl (250 µl) RO 25-6981 (150 mg/kg)
Bacteria in CSF (log10 cfu/ml) * 7.4 ± 0.7 7.3 ± 0.4 7.6 ± 0.6 7.8 ± 0.4
Clinical assessment (score) * 3.5 ± 0.8 3.7 ± 0.7 3.3 ± 0.8 3.4 ± 0.8
Mortality (%)
(hours after infection) *
21
21 ± 0.9
14
20.8 ± 1.7
33
21 ± 1.6
53
20.6 ± 1.5
Incidence of seizures (%) 25 11 33 7
Note: * Data are mean ± SDBMC Neuroscience 2003, 4 http://www.biomedcentral.com/1471-2202/4/21
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conceivable that the number of functional NDMA recep-
tors containing this subunit is already sufficiently reduced
to make its blockade less effective. Alternatively, while the
NR2B NDMA receptor may still be sufficiently functional,
it may not be directly involved in causing the apoptotic
form of neuronal injury observed in bacterial meningitis.
Given the effect of the drug on seizures, we believe that the
latter explanation is more likely.
Conclusions
In the present study, the NR2B selective NMDA antagonist
RO 25-6981 prevented the occurrence of seizures during
acute bacterial meningitis, but failed to demonstrate a
protective effect on neuronal apoptotic injury in the hip-
pocampal dentate gyrus. The potential of RO 25-6981 to
serve as neuroprotective agent in bacterial meningitis is
put into question by this study, while the drug may be of
value as an antiepileptic compound.
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Hippocampal histopathology of infant rats with pneumococ- cal meningitis 24 hours after infection Figure 1
Hippocampal histopathology of infant rats with pneu-
mococcal meningitis 24 hours after infection. Section 
of the dentate gyrus at ×100 magnification. Arrowheads 
point to apoptotic neurons in the granule cell layer; bar, 100 
µm. Insert depicts apoptotic cells at ×450 magnification with 
characteristic condensed and fragmented nuclei; bar, 25 µm. 
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